Two studies from Korea13, 17 and one from China21 showed that BIM deletion polymorphism was not an independent predictor of a poor response to EGFR‐TKIs in EGFR‐mutant NSCLC patients, whereas other studies 15, 16, 22 and studies detecting BIM mRNA expression23, 24 reported the opposite results. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.